Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Omeros (OMER) announced an update on its progress toward planned resubmission of its biologics license application, or BLA, for narsoplimab, the company’s antibody targeting ... Following data ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...